Where next for the share prices of FTSE 100 stocks BP, GlaxoSmithKline and BT?

Three FTSE 100 (INDEXFTSE:UKX) titans all report next month. Paul Summers looks at where their share prices have been and where they might go next.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

February looks like being another packed month for company updates. Among those reporting are FTSE 100 laggards BP (LSE: BP), GlaxoSmithKline (LSE: GSK) and BT (LSE: BT.A). Could we finally see their share prices recover? Here’s my take. 

FTSE 100 recovery stock? 

Oil giant BP kicks off the new month by releasing Q4 and full-year numbers on February 2. And what a year it’s been!

BP’s shares tumbled like everything else back in March’s coronavirus-induced stock market crash, Despite rising 50% since the end of October, they’re still far below where they were 12 months ago. And Covid-19 might not be entirely to blame. BP’s decision to focus more on renewable energy going forward is sound, but will also take time… and lots of cash. 

Perhaps I should be more positive. After all, a 5.5% dividend yield isn’t to be sniffed at. Moreover, we could see a revival of oil prices in 2021 as vaccine programmes are rolled out and the global economy emerges from its enforced slumber. As such, I think a confident statement on BP’s outlook from management might see the shares recapture their mojo.

Even so, it’s hard to look beyond the fact that the firm is very dependent on something beyond its control. With its substantial amount of debt, I currently consider BP a risk too far.


Hot on the heels of BP, pharmaceutical firm GlaxoSmithKline issues its Q4 and full-year results to the market on February 3. Like its FTSE 100 peer, Glaxo has hardly impressed lately.

Over the last year, the shares have fallen 20% in value. In fact, they now fetch almost exactly the same price as they did five years ago!  Investing may be a long-term endeavour but I wouldn’t begrudge any holders from feeling disgruntled, especially given how other top-tier stocks have performed in recent times.

Then again, it might be argued that those invested in the company care little for what happens to the share price, at least in the short term. On the income front, Glaxo doesn’t disappoint. An expected 80p per share cash return gives a yield of 5.7% at the current share price. And unless next month brings some unexpected news, this payout looks likely to be covered sufficiently by profits.

Trading at 12 times FY21 earnings, I continue to mull over snapping up GSK for my portfolio.


BT’s recent share price performance is arguably the most depressing of all three stocks. The communications giant’s valuation has been drifting steadily lower since 2016. Last year, it underperformed the FTSE 100. Unfortunately, I’m not so sure next month’s Q3 trading update on February 4 will reverse this trend.  

As an investor, I can forgive a company experiencing issues if I’m being compensated for my patience. On this front, however, BT currently disappoints. With a pension deficit to plug and further infrastructure investment required, dividends have been suspended.

It’s not all bad. A P/E of just 7 times earnings suggests a huge amount of bad news is already priced in. This valuation also looks seriously cheap considering BT has the largest market share of internet broadband suppliers. 

Notwithstanding this, I can see the share price moving sideways even if revenues come in better than expected. Recent news that the firm faces a £600m lawsuit alongside strike action from Openreach staff, isn’t exactly the run-up to results day management will have wanted. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Could the 9.8% M&G dividend yield get even bigger?

Christopher Ruane reckons that, although the M&G dividend yield is already close to a double-digit percentage, it could get better…

Read more »

Investing Articles

How much passive income could I earn by putting £380 a month into a Stocks and Shares ISA?

Christopher Ruane explains how he'd aim to turn a Stocks and Shares ISA into four-figure passive income streams each year.

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 passive income stocks I’m buying before an interest rate cut

With the market expecting interest rates to fall in August, time might be running out for investors looking to buy…

Read more »

Investing Articles

If I’d bought Rolls-Royce shares a year ago, here’s what I’d have now

Rolls-Royce shares have been the big FTSE 100 success story of the past 12 months and more. And there's still…

Read more »

Young female analyst working at her desk in the office
Investing Articles

If the Dow’s heading for 60,000 by 2030, can the FTSE 100 index hit 12,000?

Strategist Ed Yardeni predicts a 50% rise for America’s Dow Jones Industrial Average over six years. Can the FTSE 100…

Read more »

Investing Articles

Is the National Grid share price a once-in-a-decade opportunity?

The National Grid share price looks like a bargain. But there’s much more for investors to think about than a…

Read more »

Investing Articles

Here’s why the Rolls-Royce share price should keep gaining!

The Rolls-Royce share price is up 185% over the past 12 months, but there are a host of tailwinds that…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Buying 1,852 shares in this ultra-high yield FTSE 100 income stock would give me £1k a year

Harvey Jones is keen to load up on this blue-chip income stock that pays the highest yield on the FTSE…

Read more »